The Contribution of Health Industry to the Expansion of the Country s Development Perspective

Transcription

1 17 th Annual Conference HealthWorld 2018 The Contribution of Health Industry to the Expansion of the Country s Development Perspective Makis Papataxiarchis President, Pharma Innovation Forum, Chairman AmCham Pharmaceutical Committee Managing Director, Janssen Pharmaceutical companies of Johnson & Johnson

2 The (mistaken) general perception for our industry Pharmaceutical companies set the drug prices without taking into account of the poor third world. Given that these companies have exclusive use of these medicines, international criticism has begun in recent. Collect data on this subject and make your point of view, documenting it with both humanitarian and economic evidence.

3

4 Innovative medicines make the world a better and healthier place: they contributed approximately 73% of the improvement in life expectancy observed from Lichtenberg, F. R., Health Policy and Technology 3, pp Figure adapted from: EFPIA, Available at:

5 Improved understanding of disease and personalised care have increased patient survival A greater understanding of the molecular basis of disease has led to medicines targeted to leukemia and lymphoma subtypes, improving the outlook for patients with blood cancers in Europe a1 IMPROVED UNDERSTANDING OF THE DISEASE 1950s 1960s 1970s TODAY Disease of the Blood 5-year survival: <10% b Leukaemia Lymphoma 5-year survival: <15% b Chronic Leukaemia Acute Leukaemia Pre-leukaemia Indolent Lymphoma Aggressive Lymphoma 5-year survival: ~35% b ~40 unique Leukaemia types identified ~50 unique Lymphoma types identified Today, 230 medicines* c are in development for blood cancers in Europe Chronic Lymphocytic Leukaemia 5-year survival rates have grown to 70% d Hodgkin s Lymphoma 5-year survival rates have grown to 80% d * Medicines in Phases I through III for the treatment of all types of leukaemia and lymphoma. Source: Health Advances analysis; a PhRMA 2015 Value of Personalized Medicine; b SEER Cancer Statistics Review ( ); c PharmaProjects (accessed February 2016); d Cancer Survival in Europe Eurocare 5 Database in%20context.pdf.

6 We need a public environment that recognizes and rewards risk taking

7 The odds of success are low, which makes developing medicines a risky undertaking Of 10,000 promising molecules only 1 or 2 might make it as an approved drug 1 Cumulative average to develop successful medicine Cumulative average cost to research and develop successful medicine Number of medicinal candidates per phase of development Licensing approval billion 1 medicine available for patients Phase 3 clinical trial billion 1 2 candidates Phase 2 clinical trial million 2 5 candidates Phase 1 clinical trial million 5 10 candidates Pre-clinical testing million candidates Drug discovery million 5,000 10,000 candidates Pre-discovery 1. Adapted from ABPI. Available at:

8 Governments must look beyond medicines for real efficiency gains Changes in healthcare expenditure in Europe, % 16% 10% 5% 5% 4% 2% 0% US $ per capita Total healthcare expenditure 2005 Curative and rehabilitive care Long-term nursing care Medicines Ancillary services Therapeutic appliances Health administration and Health insurance Prevention and public health Not specified by kind Total healthcare expenditure OECD Health Statistics Database, 2015; Eurostat Database, Available at:

9 Thank you for your attention Makis Papataxiarchis President, Pharma Innovation Forum, Chairman AmCham Pharmaceutical Committee Managing Director, Janssen Pharmaceutical companies of Johnson & Johnson